Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an update.
Shanghai Bio-Heart’s subsidiary AngioCare has secured registration of its Iberis multi-electrode renal artery radiofrequency ablation catheter system in Vietnam, expanding the device’s international footprint. The system, developed for renal denervation procedures and already CE-marked in Europe, is distinctive as the only globally approved RDN product offering both transradial and transfemoral access, aiming to make outpatient RDN safer, more effective and more affordable.
The Vietnam registration was achieved in collaboration with commercialization partner Biosensors International, a Singapore-headquartered cardiovascular specialist with a broad global sales network. The move strengthens Iberis’s positioning in the fast-evolving RDN market and supports Shanghai Bio-Heart’s broader strategy to scale its technology internationally, though the company cautions that successful development and commercialization are not guaranteed and advises investors to remain prudent.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. is a China-based medical technology company focused on cardiovascular devices, primarily through its subsidiary Shanghai AngioCare Medical Technology. The Group develops minimally invasive treatment systems such as the Iberis renal denervation catheter platform, targeting global markets across Europe, Asia–Pacific and Latin America in partnership with international distributors.
Average Trading Volume: 506,280
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.11B
For an in-depth examination of 2185 stock, go to TipRanks’ Overview page.